An update on the impact of depression on the treatment of psoriasis

被引:11
|
作者
Bell, Katheryn [1 ]
Balogh, Esther A. [1 ]
Feldman, Steven R. [1 ,2 ,3 ,4 ]
机构
[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27101 USA
[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27101 USA
[3] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27101 USA
[4] Univ Southern Denmark, Dept Dermatol, Odense, Denmark
关键词
Depression; psoriasis; psoriasis treatment; adherence; treatment preferences; PATIENT-REPORTED OUTCOMES; QUALITY-OF-LIFE; DOUBLE-BLIND; PHASE-III; MODERATE; ETANERCEPT; SYMPTOMS; ANXIETY; RISK; ADALIMUMAB;
D O I
10.1080/14656566.2020.1849141
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Estimates of the prevalence of comorbid depression vary, ranging from 9 and 62%. Deterioration of mental health may emerge as a result of psoriasis; however, it is theorized that depression alone may independently predispose patients to new-onset psoriasis. Areas covered: The aim of this brief review is to explore the impact of depression on psoriasis treatment. Expert opinion: The two studies that directly assess the role of depression in psoriasis treatment outcomes are important, as unaddressed depression can undermine the success of a given treatment. This may reflect the notion that depressed individuals are less likely to be adherent. Thus, it may be valuable for clinicians to not only screen for depression, but to ensure that it is adequately treated. Our knowledge of treatment preferences in psoriasis patients with comorbid depression is limited. Expanding our understanding of preferences may allow providers to better align their recommendations to ultimately increase adherence. Additionally, given that many psoriasis treatments have an impact on depression, it may be beneficial for clinicians to evaluate patients for psychiatric risk factors to optimize the treatment regimen.
引用
收藏
页码:695 / 703
页数:9
相关论文
共 50 条
  • [1] Biosimilars in the Treatment of Psoriasis: An Update
    Puig, L.
    Carrascosa, J. M.
    Notario, J.
    ACTAS DERMO-SIFILIOGRAFICAS, 2020, 111 (10): : 809 - 814
  • [2] Secukinumab in the treatment of psoriasis: an update
    Reszke, Radomir
    Szepietowski, Jacek C.
    IMMUNOTHERAPY, 2017, 9 (03) : 229 - 238
  • [3] UPDATE OF THE TOPICAL TREATMENT OF PSORIASIS
    Carrascosa, J. M.
    Vanaclocha, F.
    Borrego, L.
    Fernandez-Lopez, E.
    Fuertes, A.
    Rodriguez-Fernandez-Freire, L.
    Zulaica, A.
    Tuneu, A.
    Caballe, G.
    Colome, E.
    Bordas, X.
    Hernanz, J. M.
    Brufau, C.
    Herrera, E.
    ACTAS DERMO-SIFILIOGRAFICAS, 2009, 100 (03): : 190 - 200
  • [4] Topical treatment of psoriasis: a systematic update
    Aschoff, R
    Wozel, G
    Meurer, M
    HAUTARZT, 2003, 54 (03): : 237 - 241
  • [5] The Psoriasis Treatment Pipeline An Overview and Update
    Hawkes, Jason E.
    Al-Saedy, Miriam
    Bouche, Nicole
    Al-Saedy, Salsabeal
    Drew, Delaney T.
    Song, Eingun James
    DERMATOLOGIC CLINICS, 2024, 42 (03) : 365 - 375
  • [6] Ustekinumab for the treatment of psoriasis: an evidence update
    Yiu, Zenas Z. N.
    Warren, Richard B.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (03) : 143 - 147
  • [7] Impact of gender on depression in patients with psoriasis
    Dabbous, Omar
    Tang, Boxiong
    Thompson, Heidi
    Rahman, Mirza
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB5 - AB5
  • [8] Impact and management of depression in psoriasis patients
    Korman, Abraham M.
    Hill, Dane
    Alikhan, Ali
    Feldman, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 147 - 152
  • [9] An update on the treatment of bipolar depression
    Azorin, Jean-Michel
    Kaladjian, Arthur
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (02) : 161 - 172
  • [10] EXERCISE AS A TREATMENT FOR DEPRESSION - AN UPDATE
    SIMONS, AD
    MCGOWAN, CR
    EPSTEIN, LH
    KUPFER, DJ
    ROBERTSON, RJ
    CLINICAL PSYCHOLOGY REVIEW, 1985, 5 (06) : 553 - 568